Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR–p53–NF-κB interactions
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR–p53–NF-κB interactions
Authors
Keywords
-
Journal
CELL CYCLE
Volume 15, Issue 22, Pages 3105-3114
Publisher
Informa UK Limited
Online
2016-09-30
DOI
10.1080/15384101.2016.1235104
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib
- (2015) Isabella Faraoni et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
- (2015) R. Ceccaldi et al. CANCER RESEARCH
- Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
- (2015) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Profile of veliparib and its potential in the treatment of solid tumors
- (2015) Lars Wagner OncoTargets and Therapy
- Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
- (2014) J. Balmaña et al. ANNALS OF ONCOLOGY
- Poly(ADP-ribose): A signaling molecule in different paradigms of cell death
- (2014) Francesca Aredia et al. BIOCHEMICAL PHARMACOLOGY
- Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53
- (2014) Ivanildce Cristiane Ireno et al. CARCINOGENESIS
- Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
- (2014) X. Wei Meng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53–MDM2 Interaction and the NF-κB Pathway
- (2014) Chunlin Zhuang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer
- (2014) Jana Heitmann et al. ORAL ONCOLOGY
- Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities
- (2013) Amos A Fatokun et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cisplatin Resistance Associated with PARP Hyperactivation
- (2013) J. Michels et al. CANCER RESEARCH
- Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines
- (2013) Tomomitsu Nasuno et al. CANCER SCIENCE
- PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs
- (2013) Ken A. Olaussen et al. LUNG CANCER
- PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy
- (2013) Jeremy P.H. Chow et al. MOLECULAR CANCER THERAPEUTICS
- PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?
- (2013) Amanda Swindall et al. Cancers
- Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
- (2013) Alice N. Weaver et al. Frontiers in Oncology
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
- (2012) Chris T. Williamson et al. EMBO Molecular Medicine
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- The role of PARP in DNA repair and its therapeutic exploitation
- (2011) M Javle et al. BRITISH JOURNAL OF CANCER
- Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent
- (2011) Diana Nguyen et al. CELL CYCLE
- Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites
- (2011) M. Zhao et al. CLINICAL CANCER RESEARCH
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways
- (2008) Anwesha Dey et al. NATURE REVIEWS DRUG DISCOVERY
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More